Related Experiment Video
Updated: May 17, 2026
Implementation of Non-invasive Point of Care Transient Elastography for Evaluation of Liver Disease in Pediatric Populations with Cystic Fibrosis
Published on: August 29, 2025
Progressive familial intrahepatic cholestasis
1Pediatric Hepatology and Liver Transplantation Unit, and Reference Centre for Rare Liver Diseases, Bicêtre Hospital, AP-HP, 78 rue du général Leclerc, 94275 Le Kremlin-Bicêtre cedex, France. emmanuel.jacquemin@bct.aphp.fr
Insights
Progressive familial intrahepatic cholestasis (PFIC) comprises genetic disorders affecting bile formation in children. Early diagnosis and treatment, including ursodeoxycholic acid (UDCA) and potentially liver transplantation, are crucial for managing this rare liver disease.
Area of Science:
- Hepatology
- Genetics
- Pediatric Gastroenterology
Background:
- Progressive familial intrahepatic cholestasis (PFIC) is a group of rare, inherited liver diseases causing impaired bile formation in children.
- These disorders lead to cholestasis, pruritus, jaundice, and often progressive liver damage, including fibrosis and end-stage liver disease.
- PFIC encompasses at least three types (PFIC1, PFIC2, PFIC3), each linked to specific gene mutations affecting hepatocellular transport systems crucial for bile acid and phospholipid secretion.
Purpose of the Study:
- To review the genetic basis, clinical manifestations, diagnostic approaches, and current management strategies for PFIC.
- To highlight the importance of early diagnosis and intervention in improving outcomes for children with PFIC.
- To discuss emerging therapeutic options and the role of liver transplantation in advanced cases.
Main Methods:
- Review of existing literature on PFIC, focusing on genetic mutations, clinical presentations, and diagnostic criteria.
- Analysis of diagnostic tools including liver imaging, histology, immunostaining (MDR3, BSEP), and genetic testing.
- Evaluation of treatment outcomes for ursodeoxycholic acid (UDCA), surgical interventions, and liver transplantation.
Main Results:
- PFIC1 and PFIC2 result from defects in bile salt secretion (FIC1 and BSEP proteins), while PFIC3 involves impaired biliary phospholipid secretion (MDR3 protein).
- Clinical presentation varies, with PFIC1/PFIC2 typically appearing earlier than PFIC3, and serum GGT levels can help differentiate PFIC3.
- Diagnosis relies on a combination of clinical findings, biochemical tests, imaging, histology, and genetic confirmation, with antenatal diagnosis possible.
- Ursodeoxycholic acid (UDCA) is a standard therapy; biliary diversion may help with pruritus in some PFIC1/PFIC2 cases, but liver transplantation remains a common definitive treatment.
Conclusions:
- PFIC represents a spectrum of genetic disorders requiring a multidisciplinary approach for diagnosis and management.
- Early identification of PFIC subtypes through genetic analysis is essential for guiding treatment decisions.
- While current therapies can manage symptoms and slow progression, liver transplantation is often necessary for end-stage disease, with ongoing research into gene therapy and other novel treatments.
Abstract:
Progressive familial intrahepatic cholestasis (PFIC) refers to a heterogeneous group of autosomal-recessive disorders of childhood that disrupt bile formation and present with cholestasis of hepatocellular origin. The exact prevalence remains unknown, but the estimated incidence varies between 1/50,000 and 1/100,000 births. Three types of PFIC have been identified and associated with mutations in hepatocellular transport-system genes involved in bile formation. PFIC1 and PFIC2 usually appear in the first months of life, whereas onset of PFIC3 may arise later in infancy, in childhood or even during young adulthood. The main clinical manifestations include cholestasis, pruritus and jaundice. PFIC patients usually develop fibrosis and end-stage liver disease before adulthood. Serum gamma-glutamyltransferase (GGT) activity is normal in PFIC1 and PFIC2 patients, but is elevated in PFIC3 patients. Both PFIC1 and PFIC2 are caused by impaired bile salt secretion due to defects in ATP8B1 encoding the FIC1 protein and in ABCB11 encoding bile salt export pump (BSEP) protein, respectively. Defects in ABCB4, encoding multidrug resistance 3 protein (MDR3), impair biliary phospholipid secretion, resulting in PFIC3. Diagnosis is based on clinical manifestations, liver ultrasonography, cholangiography and liver histology, as well as on specific tests to exclude other causes of childhood cholestasis. MDR3 and BSEP liver immunostaining, and analysis of biliary lipid composition should help to select PFIC candidates for whom genotyping could be proposed to confirm the diagnosis. Antenatal diagnosis may be proposed for affected families in which a mutation has been identified. Ursodeoxycholic acid (UDCA) therapy should be initiated in all patients to prevent liver damage. In some PFIC1 and PFIC2 patients, biliary diversion may also relieve pruritus and slow disease progression. However, most PFIC patients are ultimately candidates for liver transplantation. Monitoring of liver tumors, especially in PFIC2 patients, should be offered from the first year of life. Hepatocyte transplantation, gene therapy and specific targeted pharmacotherapy may represent alternative treatments in the future.
Related Concept Videos
01:25Chronic Pancreatitis I: Introduction
01:24Chronic Pancreatitis I: Introduction
Pancreatitis is the inflammation of the pancreas, which occurs when the immune system becomes active and causes swelling, pain, and disruptions in organ function. Pancreatitis can manifest as either an acute or chronic condition.
Acute pancreatitis arises suddenly and lasts for a brief duration, while chronic pancreatitis is a long-term affliction...
01:21Chronic Pancreatitis II: Pathophysiology
01:24Cirrhosis II: Pathophysiology
01:20Cholecystitis
01:23Cirrhosis I: Introduction